The spectrum of oculocutaneous disease : Part I. Infectious, inflammatory, and genetic causes of oculocutaneous disease - 16/04/14
Abstract |
Many skin diseases are associated with ocular findings, emphasizing the need for dermatologists to be fully aware of their presence, and as a result, avoid overlooking conditions with potentially major ocular complications, including blindness. We review important oculocutaneous disease associations with recommendations for the management of the ocular complications and appropriate referral to our ophthalmology colleagues. Part I of this 2-part review focuses on the infectious, inflammatory, and genetic relationships.
Le texte complet de cet article est disponible en PDF.Key words : autoimmune, dermatology, genetic, infection, inflammatory, oculocutaneous, ophthalmology
Plan
Funding sources: None. |
|
Dr Alan Menter has reported the following financial relationships: Abbott Laboratories, Consultant, Honorarium; Abbott Laboratories, Speaker, Honorarium; Abbott Laboratories, Principle Investigator, Honorarium; Abbott Laboratories, Advisory Board, Grants/Research Funding; AbbVie, Speaker, Fees; Amgen, Advisory Board, Grants/Research Funding; Amgen, Speaker, Honorarium; Astellas Pharma US, Inc, Advisory Board, Honorarium; Astellas Pharma US, Inc, Consultant, Grants/Research Funding; Celgene Corporation, Principal Investigator, Grants/Research Funding; Centocor Ortho Biotech, Inc, Consultant, Grants/Research Funding; Centocor Ortho Biotech, Inc, Advisory Board, Honorarium; Eli Lilly and Company, Principal Investigator, Grants/Research Funding; Galderma Laboratories, Advisory Board, Honorarium; Galderma Laboratories, Speaker, Honorarium; Genentech, Inc, Advisory Board, Grants/Research Funding; Novartis Pharmaceuticals Corp, Principal Investigator, Grants/Research Funding; Novo Nordisk A/S, Principal Investigator, Grants/Research Funding; Pfizer, Inc, Speaker, Honorarium; Pfizer, Inc, Advisory Board, Honorarium; Pfizer, Inc, Principal Investigator, Grants/Research Funding; Promius Pharma, LLC, Principal Investigator, Grants/Research Funding; Stiefel a GSK company, Principal Investigator, Grants/Research Funding; Syntrix, Principal Investigator, Grants/Research Funding; Warner Chilcott, Advisory Board, Honorarium; Warner Chilcott, Advisory Board, Honorarium. Dr Richard B. Warren has reported the following financial relationships: Abbvie, Advisory Board, Honorarium; AbbVie, Speaker, Honorarium; Amgen, Consultant, Honorarium; Leo, Advisory Board, Honorarium; Leo, Speaker, Honorarium; Pfizer, Inc, Advisory Board, Honorarium; Pfizer, Inc, Speaker, Honorarium; Novartis Pharmaceuticals Corp, Advisory Board, Honorarium; Novartis Pharmaceuticals Corp, Speaker, Honorarium; Novartis Pharmaceuticals Corp, Principal Investigator, Honorarium; Janssen, Advisory Board, Honorarium; Janssen, Speaker, Honorarium. Drs Amanda Abramson, Mary E. Horner and Susan Swanson have no conflicts of interest to disclose. |
Vol 70 - N° 5
P. 795.e1-795.e25 - mai 2014 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?